Myriad Sues Ambry Over Supreme Court-Backed Patents

Law360, San Francisco (July 9, 2013, 9:17 PM EDT) -- Myriad Genetics Inc. sued Ambry Genetics Corp. in Utah federal court Tuesday, alleging it launched cancer-testing products that infringe 10 Myriad patents on synthetic DNA and methods of use for two breast cancer genes, including four patents recently upheld by the U.S. Supreme Court.

Ambry's new testing products, including BRCAplus, BreastNext, OvaNext and CancerNext, purportedly copy technology Myriad either patented or licensed in relation to its identification of the BRCA1 and BRCA2 genes and mutations, which increase women's risk of developing breast or ovarian cancer, according to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.